WC
SLNO

Wexford Capital’s Soleno Therapeutics SLNO Stock Holding History

Wexford Capital’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-667
Closed -$19K – 324
2020
Q4 		$19K Sell
667
-690
-51% -$19.9K ﹤0.01% 299
2020
Q3 		$51K Buy
+1,357
New +$39.7K 0.01% 166

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Wexford Capital's SLNO Position: Q1 2021 in Review

Wexford Capital sold out of Soleno Therapeutics (SLNO) in Q1 2021, closing a stake of 667 shares — an estimated $19K sold.

Wexford Capital first reported a position in SLNO in Q3 2020 and held it in 2 quarters. The position peaked at $51K in Q3 2020. 63 funds tracked by Wall St. Rank hold SLNO as of Q1 2021.

  • Wexford Capital reported no remaining Soleno Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 667 Soleno Therapeutics shares in Q1 2021, an estimated $19K.
  • Wexford Capital first reported a position in Soleno Therapeutics in Q3 2020 and held it in 2 quarters.
  • Wexford Capital's Soleno Therapeutics position peaked at $51K in Q3 2020.
  • 63 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.